Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)

European Journal of Cancer

Volumn 50, Issue 2, 2014, Pages 302-308

  Brahmer, J R ^a   Lee, J W ^b   Traynor, A M ^c   Hidalgo, M M ^d   Kolesar, J M ^c   Siegfried, J M ^e   Guaglianone, P P ^f   Patel, J D ^g   Keppen, M D ^h   Schiller, J H ⁱ  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d Madrid Sanchinarro University Hospital   (Spain)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f Decatur Memorial Hospital   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h Sanford Medical Center   (United States)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Erlotinib; NSCLC; Phase II

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ERLOTINIB; HEMOGLOBIN; MITOGEN ACTIVATED PROTEIN KINASE;

ACNE; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT DISORDER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; DYSPHAGIA; ERYTHEMA MULTIFORME; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPONATREMIA; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; ORAL MUCOSITIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SKIN EXFOLIATION; SKIN PRURITUS; TREATMENT RESPONSE; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84891827637     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.10.006     Document Type: Article

References (23)

1. M.H. Cohen, G.A. Williams, and R. Sridhara et al. United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets Clin Cancer Res 10 2004 1212 1218
2. F.A. Shepherd, J. Rodrigues Pereira, and T. Ciuleanu et al. Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
3. T.J. Lynch, D.W. Bell, and R. Sordella et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
4. J.G. Paez, P.A. Janne, and J.C. Lee et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
5. T.S. Mok, Y.L. Wu, and S. Thongprasert et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
6. R. Rosell, E. Carcereny, and R. Gervais et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
7. M.S. Tsao, A. Sakurada, and J.C. Cutz et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
8. G. Giaccone, M. Gallegos Ruiz, and T. Le Chevalier et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study Clin Cancer Res 12 2006 6049 6055
9. R. Perez-Soler, A. Chachoua, and L.A. Hammond et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 2004 3238 3247
10. F.R. Hirsch, M. Varella-Garcia, and P.A. Bunn Jr et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer J Clin Oncol 24 2006 5034 5042
11. F. Cappuzzo, E. Magrini, and G.L. Ceresoli et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer J Natl Cancer Inst 96 2004 1133 1141
12. C.P. Schneider, D. Heigener, and K. Schott-von-Romer et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST study J Thorac Oncol 3 2008 1446 1453
13. J.M. Amann, J.W. Lee, and H. Roder et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503 J Thorac Oncol 5 2010 169 178
14. M.M. Oken, R.H. Creech, and D.C. Tormey et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
15. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
16. Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Event (CTCAE), Version 3.0, Division of Cancer Treatment and Diagnosis (DCTD), NCI, National Institute of Health (NIH), Department of Health and Human Services (DHHS). http://ctep.info.nih.gov/protocoldevelopment/ electronicapplications/docs/ctcaev3.pdf.
17. A. Maitra, R. Ashfaq, and C.R. Gunn et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging Am J Clin Pathol 118 2002 194 201
18. A. Maitra, D. Wanzer, and A.G. Weinberg et al. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas Cancer 92 2001 677 683
19. M. Ronaghi Pyrosequencing sheds light on DNA sequencing Genome Res 11 2001 3 11
20. D.M. Jackman, B.Y. Yeap, and N.I. Lindeman et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer J Clin Oncol 25 2007 760 766
21. J. Li, M. Zhao, and P. He et al. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes Clin Cancer Res 13 2007 3731 3737
22. A.C. Mita, K. Papadopoulos, and M.J. de Jonge et al. Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer Br J Cancer 105 2011 938 944
23. M. Hamilton, J.L. Wolf, and J. Rusk et al. Effects of smoking on the pharmacokinetics of erlotinib Clin Cancer Res 12 2006 2166 2171